Skip to main content
Clinical Trials/CTRI/2024/01/061995
CTRI/2024/01/061995Not yet recruitingPhase 4

Effectiveness and safety of Selective serotonin Reuptake inhibitor (SSRI) alone vsSSRI with Methylphenidate sustained release in the patients with moderate to severe obsessive compulsive disorder(OCD) - nil

MGM Medical College and Hospital0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Patients with OCD disorder who fulfill the diagnostic criteria according to DSM-5.
  • Patient with Total score more than 16 in Yale-Brown obsessive-compulsive disorder scale.
  • Patients aged between 18-85 years.
  • Subjects who Provide written informed consent, willing and able to comply with all aspects of the protocol

Exclusion Criteria

  • Patient with prior allergic reaction on exposure to Methylphenidate
  • OCD patients with psychiatric illness except depression and anxiety
  • Substance abuse or Dependence within the past 6 months except nicotine
  • History of a seizure disorder or other major neurologic disease.
  • Patients with psychiatric Instability that made participants potentially unsafe in the evaluating psychiatrists judgment.
  • Patients with pregnancy or breastfeeding
  • Patients with known chronic medical illness like, Diabetes Mellitus, Hypertension, Cerebro-vascular Accident, Ischemic Heart Disease, Coronary Artery Disease etc.
  • Patients not in a condition to give written informed consent E.g.: Delirium, intellectual disability etc.

Investigators

Similar Trials